Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome

Pediatric Obesity

Volumn 12, Issue 3, 2017, Pages 221-228

  Salehi, P ^a   Hsu, I ^b   Azen, C G ^b   Mittelman, S D ^b   Geffner, M E ^b   Jeandron, D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

appetite; Byetta; exenatide; ghrelin; hyperphagia; Prader Willi syndrome

Indexed keywords

EXENDIN 4; GASTROINTESTINAL HORMONE; GHRELIN; INCRETIN; PEPTIDE; VENOM;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; APPETITE; ARTICLE; BODY MASS; BODY WEIGHT; CALIFORNIA; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOOD INTAKE; HORMONE BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MALE; MEDICATION COMPLIANCE; OBESITY; OPEN STUDY; PILOT STUDY; PRADER WILLI SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; YOUNG ADULT; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HYPERPHAGIA; PRADER-WILLI SYNDROME;

ADOLESCENT; ADULT; APPETITE; BODY MASS INDEX; BODY WEIGHT; FEMALE; GHRELIN; HUMANS; HYPERPHAGIA; INCRETINS; LONGITUDINAL STUDIES; MALE; OBESITY; PEPTIDES; PRADER-WILLI SYNDROME; VENOMS; YOUNG ADULT;

EID: 84963644364     PISSN: 20476302     EISSN: 20476310     Source Type: Journal    
DOI: 10.1111/ijpo.12131     Document Type: Article

References (30)

1. Lionti T, Reid SM, White SM, Rowell MM. A population-based profile of 160 Australians with Prader–Willi syndrome: trends in diagnosis, birth prevalence and birth characteristics. Am J Med Genet A 2014; 167A: 371–378.
2. Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader–Willi syndrome. Nature 1989; 342: 281–285.
3. Holm VA, Cassidy SB, Butler MG, et al. Prader–Willi syndrome: consensus diagnostic criteria. Pediatrics 1993; 91: 398–402.
4. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader–Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792–798.
5. Holland AJ, Treasure J, Coskeran P, Dallow J, Milton N, Hillhouse E. Measurement of excessive appetite and metabolic changes in Prader–Willi syndrome. Int J Obes Relat Metab Disord 1993; 17: 527–532.
6. Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H. Relationship between clinical and genetic diagnosis of Prader–Willi syndrome. J Med Genet 2002; 39: 926–932.
7. Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader–Willi syndrome. Am J Med Genet A 2011; 155A: 1040–1049.
8. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations for the diagnosis and management of Prader–Willi syndrome. J Clin Endocrinol Metab 2008; 93: 4183–4197.
9. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908–913.
10. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
11. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader–Willi syndrome. Nat Med 2002; 8: 643–644.
12. Haqq AM, Farooqi IS, O'Rahilly S, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader–Willi syndrome. J Clin Endocrinol Metab 2003; 88: 174–178.
13. Paik KH, Jin DK, Song SY, et al. Correlation between fasting plasma ghrelin levels and age, body mass index (BMI), BMI percentiles, and 24-hour plasma ghrelin profiles in Prader–Willi syndrome. J Clin Endocrinol Metab 2004; 89: 3885–3889.
14. Feigerlova E, Diene G, Conte-Auriol F, et al. Hyperghrelinemia precedes obesity in Prader–Willi syndrome. J Clin Endocrinol Metab 2008; 93: 2800–2805.
15. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–1100.
16. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33: 1173–1175.
17. Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013; 167: 355–360.
18. Perez-Tilve D, Gonzalez-Matias L, Alvarez-Crespo M, et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007; 56: 143–151.
19. van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 2014; 63: 4186–4196.
20. Seetho IW, Jones G, Thomson GA, Fernando DJ. Treating diabetes mellitus in Prader–Willi syndrome with Exenatide. Diabetes Res Clin Pract 2011; 92: e1–2.
21. Sze L, Purtell L, Jenkins A, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader–Willi syndrome. J Clin Endocrinol Metab 2011; 96: E1314–1319.
22. Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader–Willi syndrome. Obesity (Silver Spring) 2007; 15: 1816–1826.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
24. Zipf WB, O'Dorisio TM, Cataland S, Dixon K. Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader–Willi syndrome. J Clin Endocrinol Metab 1983; 57: 1074–1080.
25. Tomita T, Greeley G Jr, Watt L, Doull V, Chance R. Protein meal-stimulated pancreatic polypeptide secretion in Prader–Willi syndrome of adults. Pancreas 1989; 4: 395–400.
26. Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, Malecki MT. Liraglutide therapy in Prader–Willi syndrome. Diabet Med 2011; 28: 755–756.
27. Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader–Willi syndrome. Endocr J 2012; 59: 889–894.
28. Fintini D, Grugni G, Brufani C, Bocchini S, Cappa M, Crino A. Use of GLP-1 receptor agonists in Prader–Willi syndrome: report of six cases. Diabetes Care 2014; 37: e76–77.
29. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150–156.
30. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595–2604.